Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EUA Draft Guidance: FDA Wants ‘Transition Implementation Plan’ Along With Marketing Submission

Also: Makers of life-supporting, life-sustaining EUA devices should file “notification of intent” with agency

Executive Summary

In a long-awaited draft guidance document, the US agency lays bare its thinking on how companies can best ensure that their products granted emergency use authorization status can still be sold post-pandemic (or not).

You may also be interested in...

FDA Finalizes Guidance Documents Aimed At Easing Post-Pandemic Regulatory Transitions

The documents describe the US agency’s preferred approach toward products cleared under EUAs or other alternate approaches during the COVID-19 public health emergency.

FDA Reopens Pre-Submissions For Non-COVID-19 Products

The US agency now has the staff it needs to review pre-submissions for devices that aren’t related to the pandemic, says a new blog post from device center director Jeff Shuren and Office of Product Evaluation and Quality director William Maisel.

FDA Outlines Phased Approach To Return Products To Full Compliance After Emergency Use Ends

The US FDA says in a new draft guidance document that makers of a variety of devices and diagnostics that were given wide enforcement berth by the agency to use their products to respond to COVID-19 must eventually transition back to full regulatory compliance under a proposed three-phase plan.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts